Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase
Andrew Hinman,Charles R. Holst,Joey C. Latham,Joel J. Bruegger,Gözde Ulas,Kevin P. McCusker,Akiko Amagata,Dana Davis,Kevin G. Hoff,Amanda H. Kahn-Kirby,Virna Kim,Yuko Kosaka,Edgar Lee,Stephanie A. Malone,Janet J. Mei,Steve James Richards,Veronica Rivera,Guy Miller,Jeffrey K. Trimmer,William D. Shrader
DOI: https://doi.org/10.1371/journal.pone.0201369
IF: 3.7
2018-08-15
PLoS ONE
Abstract:Ferroptosis is a form of programmed cell death associated with inflammation, neurodegeneration, and ischemia. Vitamin E (alpha-tocopherol) has been reported to prevent ferroptosis, but the mechanism by which this occurs is controversial. To elucidate the biochemical mechanism of vitamin E activity, we systematically investigated the effects of its major vitamers and metabolites on lipid oxidation and ferroptosis in a striatal cell model. We found that a specific endogenous metabolite of vitamin E, alpha-tocopherol hydroquinone, was a dramatically more potent inhibitor of ferroptosis than its parent compound, and inhibits 15-lipoxygenase via reduction of the enzyme's non-heme iron from its active Fe3+ state to an inactive Fe2+ state. Furthermore, a non-metabolizable isosteric analog of vitamin E which retains antioxidant activity neither inhibited 15-lipoxygenase nor prevented ferroptosis. These results call into question the prevailing model that vitamin E acts predominantly as a non-specific lipophilic antioxidant. We propose that, similar to the other lipophilic vitamins A, D and K, vitamin E is instead a pro-vitamin, with its quinone/hydroquinone metabolites responsible for its anti-ferroptotic cytoprotective activity.
multidisciplinary sciences